STERIS plc (Ireland) (STE) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $212.98, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.9%.
STERIS (Ireland) is a global provider of infection prevention and sterilization products/services for healthcare, contract sterilization (AST), and life sciences customers. Three segments earn revenue from consumables, equipment maintenance, and outsourced reprocessing services... Read more
Hold if already holding. Not a fresh buy at $212.98, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.9%. Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Score 5.8/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — STERIS plc (Ireland)
Latest news
- NEWS STERIS Keeps Quarterly Dividend at $0.63 a Share, Payable June 26 to Shareholders of Record on June 8 - marketscreener.c — marketscreener.com neutral
- NEWS STERIS appoints Pierre Boulud to board of directors By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS STERIS appoints Pierre Boulud to board of directors By Investing.com - Investing.com Australia — Investing.com Australia neutral
- NEWS STERIS Appoints Pierre Boulud to Board of Directors - The Globe and Mail — The Globe and Mail positive
- NEWS Steris plc stock (IE00BFY8C754): Medical sterilization leader in focus for US investors - AD HOC NEWS — AD HOC NEWS positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierethylene oxide and cobalt-60 (single-source AST materials)10-K Item 1: 'We have long-term supply contracts for certain materials...such as ethylene oxide ("EO") and radioisotope cobalt-60 ("cobalt-60"), which are necessary to our AST operations.'
Material Events(8-K, last 90d)
- 2026-05-07Item 5.02LOWRichard C. Breeden not standing for re-election at 2026 AGM (no disagreement cited). Pierre Boulud (CEO of bioMérieux) appointed as new director effective May 5, 2026, joining Audit Committee and R&D Committee.SEC filing →
- 2026-04-06Item 5.02LOWAmendment to Transition Agreement with former CFO Michael J. Tokich extends part-time senior financial advisor role through March 31, 2027 at reduced $60,000 annual salary. Routine transition arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $212.98, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.9%. Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Target $223.47 (+4.9%), stop $203.14 (−4.8%), A.R:R 0.8:1. Score 5.8/10, moderate confidence.
Take-profit target: $223.47 (+4.9% upside). Target $223.47 (+4.9%), stop $203.14 (−4.8%), A.R:R 0.8:1. Stop-loss: $203.14.
Concentration risk — Supplier: ethylene oxide and cobalt-60 (single-source AST materials); Thin upside margin: 4.9%; Below 200-MA, MA slope -1.2%/30d (confirmed downtrend).
STERIS plc (Ireland) trades at a P/E of 26.5 (forward 17.3). TrendMatrix value score: 5.7/10. Verdict: Hold.
15 analysts cover STE with a consensus score of 3.9/5. Average price target: $257.
What does STERIS plc (Ireland) do?STERIS (Ireland) is a global provider of infection prevention and sterilization products/services for healthcare,...
STERIS (Ireland) is a global provider of infection prevention and sterilization products/services for healthcare, contract sterilization (AST), and life sciences customers. Three segments earn revenue from consumables, equipment maintenance, and outsourced reprocessing services with no single customer exceeding 10% of any segment's revenues.